Literature DB >> 35978918

Myasthenia gravis that has developed long after radical resection of lung cancer: A case report.

Shinichiro Okauchi1, Ayako Shioya2, Kesato Iguchi3, Kinya Furukawa4, Hiroaki Satoh1.   

Abstract

Myasthenia gravis (MG) is the most common disorder of neuromuscular transmission and is a heterogeneous disorder generally caused by auto-antibody to the nicotinic acetylcholine receptor. The current study presented a rare case of MG that occurred a long time after surgical resection of lung cancer. A 58-year-old man with lung adenocarcinoma underwent upper lobectomy and mediastinal lymph node dissection. Severe myasthenic symptoms began 7 years after the operation, and emergent mechanical ventilation was needed because of myasthenic crises. Levels of serum anti-acetylcholine receptor antibody were high and typical decremental responses to repetitive stimulation on electromyography were observed. Appropriate therapies for a severe acute condition were performed, and MG has been controlled for 6 years since then. There is no recurrence of lung cancer or appearance of thymoma. In conclusion, although very rare, physicians should be aware of MG as a potential comorbidity developing in patients with a history of lung cancer.
Copyright © 2020, Spandidos Publications.

Entities:  

Keywords:  adenocarcinoma; curative resection; lung cancer; myasthenia gravis; postoperative

Year:  2022        PMID: 35978918      PMCID: PMC9366303          DOI: 10.3892/etm.2022.11492

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.751


  19 in total

1.  Myasthenia gravis associated with small cell carcinoma of the lung.

Authors:  P B Hazard; T E Bertorini; J P Griffin
Journal:  J Tenn Med Assoc       Date:  1986-05

Review 2.  Myasthenia gravis: An emerging toxicity of immune checkpoint inhibitors.

Authors:  D Makarious; K Horwood; J I G Coward
Journal:  Eur J Cancer       Date:  2017-06-27       Impact factor: 9.162

3.  Myasthenia gravis with a paraneoplastic marker.

Authors:  J A Leavitt
Journal:  J Neuroophthalmol       Date:  2000-06       Impact factor: 3.042

4.  Myasthenia gravis complicated with lung cancer and middle mediastinal thymoma.

Authors:  Masaya Takizawa; Makoto Oda; Isao Matsumoto; Ryuichi Waseda; Nobuyoshi Tanaka; Go Watanabe
Journal:  Asian Cardiovasc Thorac Ann       Date:  2012-08

5.  Lung cancer associated with seronegative myasthenia gravis.

Authors:  Kyoko Niimi; Eiichiro Nagata; Naoko Murata; Masako Sato; Jun Tanaka; Yukihiro Horio; Hiroto Takiguchi; Hiromi Tomomatsu; Katsuyoshi Tomomatsu; Naoki Hayama; Tsuyoshi Oguma; Takuya Aoki; Tetsuya Urano; Tadashi Abe; Chie Inomoto; Shunya Takizawa; Koichiro Asano
Journal:  Intern Med       Date:  2015-06-01       Impact factor: 1.271

6.  [A case of small cell lung cancer that developed during therapy for myasthenia gravis].

Authors:  R Miyoshi; Y Yamaji; S Shima; J Fujita; H Okada; J Takahara
Journal:  Nihon Kyobu Shikkan Gakkai Zasshi       Date:  1995-04

7.  Seropositive myasthenia gravis associated with small-cell lung carcinoma.

Authors:  Masayuki Ohira; Dushin Jeong; Shin J Oh
Journal:  J Clin Neurol       Date:  2011-03-31       Impact factor: 3.077

8.  Acetylcholine receptor antibody-positive myasthenia gravis associated with small-cell lung cancer: A case report.

Authors:  Masahiro Yamasaki; Kunihiko Funaishi; Naomi Saito; Tomomi Yonekawa; Takemori Yamawaki; Daisuke Ihara; Wakako Daido; Sayaka Ishiyama; Naoko Deguchi; Masaya Taniwaki; Noboru Hattori
Journal:  Medicine (Baltimore)       Date:  2018-04       Impact factor: 1.889

Review 9.  Autoimmune Channelopathies at Neuromuscular Junction.

Authors:  Kun Huang; Yue-Bei Luo; Huan Yang
Journal:  Front Neurol       Date:  2019-05-17       Impact factor: 4.003

10.  Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature.

Authors:  Houssein Safa; Daniel H Johnson; Van Anh Trinh; Theresa E Rodgers; Heather Lin; Maria E Suarez-Almazor; Faisal Fa'ak; Chantal Saberian; Cassian Yee; Michael A Davies; Sudhakar Tummala; Karin Woodman; Noha Abdel-Wahab; Adi Diab
Journal:  J Immunother Cancer       Date:  2019-11-21       Impact factor: 13.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.